Investors
Directors’ Dealings
Share dealings of the Board of Executive Directors and Supervisory Board
(Directors’ dealings to be notified and publicly disclosed under Article 19(1) of the EU Market Abuse Regulation 596/2014 (MAR))
As legally stipulated by Article 19(1) MAR, all members of the Board of Executive Directors and the Supervisory Board as well as close family relatives are required to disclose the purchase or sale of financial instruments of BASF SE (for example, shares, bonds, options, forward contracts, swaps) to the German Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht) and to the company if transactions within the calendar year exceed the threshold of €20,000. In 2024, a total of 16 purchases by members of the Board of Executive Directors and the Supervisory Board of BASF SE and members of their families subject to disclosure were reported as directors’ dealings, involving between 1,032 and 21,279 BASF shares or BASF ADRs (American Depositary Receipts). The price per share was between €42.61 and €48.57. The volume of the individual transactions was between €49,965.93 and €999,666.13.
Share ownership by members of the Board of Executive Directors and the Supervisory Board
No member of the Board of Executive Directors or the Supervisory Board owns shares in BASF SE and related options or other derivatives that account for 1% or more of the share capital. Furthermore, the total volume of BASF SE shares and related financial instruments held by all members of the Board of Executive Directors and the Supervisory Board accounts for less than 1% of the shares issued by the company.
Closed periods
30 calendar days before public disclosure of a quarterly statement on the first or third quarter, half-year financial report or annual report of BASF SE.
Next closed periods:
- June 30, 2025 to July 30, 2025
- September 29, 2025 to October 29, 2025
- January 28, 2026 to February 27, 2026
- March 31, 2026 to April 30, 2026
Managers’ transactions
| Name | Date and Place of Transaction | Type of Transaction | Price per Item | Total Amount/ Currency | Reason for Disclosure Requirement/ Position | Description of Financial Instrument | ISIN |
| Dr. Dirk Elvermann | 06/03/2025 Tradegate | Purchase | €41.62 | €403,707.00 | Board Member | Shares of BASF SE | DE000BASF111 |
|
Dr. Kurt Bock |
05/05/2025 Xetra | Purchase | €42.43 | €124,969.01 | Supervisory Board Member | Shares of BASF SE |
DE000BASF111 |
|
Prof. Dr. Alexander Asenkerschbaumer |
05/05/2025 Xetra | Purchase | €42.43 | €74,981.41 | Supervisory Board Member | Shares of BASF SE |
DE000BASF111 |
|
Alessandra Genco |
05/05/2025 Xetra | Purchase | €42.43 | €49,987.61 | Supervisory Board Member | Shares of BASF SE |
DE000BASF111 |
|
Liming Chen |
05/05/2025 Xetra | Purchase | €42.43 | €49,987.61 | Supervisory Board Member | Shares of BASF SE |
DE000BASF111 |
|
Prof. Dr. Thomas Carell |
05/05/2025 Xetra | Purchase | €42.43 | €49,987.61 | Supervisory Board Member | Shares of BASF SE |
DE000BASF111 |
|
Tamara Weinert |
05/05/2025 Xetra | Purchase |
€42.43 |
€37,469.49 | Supervisory Board Member | Shares of BASF SE |
DE000BASF111 |
| Dr. Markus Kamieth | 05/05/2025 Xetra | Purchase | €42.54 | €901,767.98 | Board Member | Shares of BASF SE | DE000BASF111 |
| Dr. Katja Scharpwinkel | 05/05/2025 Xetra | Purchase | €42.57 | €315,003.05 | Board Member | Shares of BASF SE | DE000BASF111 |
| Dr. Dirk Elvermann | 05/05/2025 Tradegate | Purchase | €43.35 | €107,986.00 | Board Member | Shares of BASF SE | DE000BASF111 |